Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy

Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving non-malignant cells unharmed. With the first U.S. Food and Drug Administration-approved OV, dozens of clinical trials ongoing, and an abundance of translational research in the field, OV therapy is pois...

Descripción completa

Detalles Bibliográficos
Autores principales: Bressy, Christian, Hastie, Eric, Grdzelishvili, Valery Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415316/
https://www.ncbi.nlm.nih.gov/pubmed/28480326
http://dx.doi.org/10.1016/j.omto.2017.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415316/
https://www.ncbi.nlm.nih.gov/pubmed/28480326
http://dx.doi.org/10.1016/j.omto.2017.03.002

Ejemplares similares